OSCR

GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome.

Overview

Authors: Ina-Beate Wanner1, Julia Halford1, Jonathan Lopez1, Sean Shen2, Yu Chen3, Hayden Zhao1, Carolina Salas1, Rachel Ogorzalek Loo2, Steven Robicsek4, Benjamin M Ellingson5, Jeffrey Gornbein6, Timothy E Van Meter7, Gerry Shaw8,9, Joseph A Loo2, Paul M Vespa10
ORCID iDs: Ina-Beate Wanner
  1. Semel Institute for Neuroscience and Human Behavior, Intellectual and Developmental Disability Center (IDDRC), Brain Injury Research Center (BIRC), David Geffen School of Medicine, UCLA, 635 Charles E. Young Drive South, NRB315, Los Angeles, CA 90095 USA
  2. Department of Chemistry and Biochemistry, Molecular Biology Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
  3. Molecular Instrumentation Center (MIC), Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA USA
  4. Department of Anesthesiology, Neurosurgery and Neuroscience, University of Florida, Gainesville, FL 32610-0254 USA
  5. Department of Radiological Sciences, Geffen School of Medicine, UCLA, Los Angeles, CA USA
  6. Department of Computational Medicine, Statistics Core of the Department of Medicine, School of Public Health, UCLA, Los Angeles, CA USA
  7. BRAINBox Solutions, Inc., Richmond, VA 23219 USA
  8. Department of Neuroscience, University of Florida College of Medicine, Gainesville, FL 32610 USA
  9. EnCor Biotechnology Inc., Gainesville, FL 32608 USA
  10. Department Neurology and Neurosurgery, BIRC, David Geffen School of Medicine, Ronald Reagan Medical Center, UCLA, Los Angeles, CA USA
Institutions: University of California, Los Angeles (United States); University of Florida Health (United States); University of Florida (United States); Ronald Reagan UCLA Medical Center (United States)
Journal: Acta neuropathologica communications, volume 14, issue 1, article 101
Dates: received 10 November 2025; accepted 21 January 2026; published online 24 April 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1186/s40478-026-02240-y · PMID 42032706 · PMCID PMC13107622 · OpenAlex W4412835672
Open access: gold, a free copy (OpenAlex)
Status: data only
Categories: other (modality), human (organism), traumatic brain injury (population)
Methods: Connectivity, Statistics, Machine learning, fMRI & imaging, Smoothing, state filtering, decompositions
Keywords: Neurotrauma, Pathomechanism, Neurodegeneration, Biomarker profiling, Proteostasis, Monitoring, Citrullination, Astrocytopathy
MeSH: Astrocytes*, Brain Injuries, Traumatic*, Glial Fibrillary Acidic Protein*, Adult, Aged, Biomarkers, Female, Humans, Male, Middle Aged, Protein Processing, Post-Translational, Proteolysis, Young Adult (* major topic)
Topic: Traumatic Brain Injury and Neurovascular Disturbances (Neurology, Medicine), according to OpenAlex
Funding: Dana Foundation ("First in man" award # 20182601: "Clinical study and trauma culture model experiments", Clinical Neuroscience "First in man" award # 20182601: "Clinical study and trauma culture model experiments", Clinical Neuroscience “First in man” award # 20182601: “Clinical study and trauma culture model experiments”, “First in man” award # 20182601: “Clinical study and trauma culture model experiments”); National Institute of Health (NIH), Institute of Neuronal Disorders and Stroke (NINDS), Small Business Innovation Research, SBIR (# 1R43NS106972-01 “Validation and GFAP proteoform characterization for assay use”, # 1R43NS106972-01 "Validation and GFAP proteoform characterization for assay use"); National Institute of Health (NIH), Institute of Neuronal Disorders and Stroke (NINDS) (R01 NS052831 "Biochemical markers of severe traumatic brain injury", R01 NS052831 “Biochemical markers of severe traumatic brain injury”); Abbott Diagnostics (Sponsored Research Agreement: "GFAP fragment analyses", Sponsored Research Agreement: “GFAP fragment analyses”); Brain Injury Research Center (BIRC), State of California ("Clinical study and trauma culture model experiments", “Clinical study and trauma culture model experiments”); BRAINBox Solutions Inc., Richmond VA, USA (Sponsored Research Agreement: “Validation studies and patent licensing”, Sponsored Research Agreement: "Validation studies and patent licensing"); NINDS NIH HHS (R43 NS106972)
Citations: cited by 3 papers (Europe PMC); 108 references in the paper
Research resources: RRID:AB_3678889

Abstract

Glial fibrillary acidic protein (GFAP) is a significant clinical biomarker of traumatic brain injury (TBI), yet understanding the nature, timing, and impact of its degraded and modified products would inform clinical utility. We report novel GFAP breakdown products (BDPs) and post-translational modifications (PTMs) that are unique to TBI including fragment- and patient-specific citrullination signatures that destabilize GFAP filaments. GFAP and its fragments were sequenced by mass spectrometry (MS) from severe TBI patients’ cerebrospinal fluid (CSF) and sera, identifying two distinct TBI-specific jointly generated product sets within the rod-domain covering coil1 (20–26 kDa) and coil2 (15–19 kDa). Their endings differed from GFAP fragments described in Alzheimer’s and Alexander disease. Label-free quantification showed biofluid co-product abundance differences with coil1-BDPs enriched over coil2-BDPs. Coil imbalance was independently confirmed by immunoblot densitometry in twenty-three TBI patients. Measurements over ten days showed injury day peaks of full-length and end-clipped GFAP fragments, while proteolytic 37/39 kDa and small fragments remained elevated. Six-month outcome (Extended Glasgow Outcome Scale) correlated with GFAP fragments, whereas levels of uncleaved and end-clipped GFAP did not. A human astrocyte culture trauma model provided mechanistic insights linking fluid GFAP levels, subcellular localization, and injury-induced astrocytopathy. A new cleavage site between the two coils was identified through selective epitope loss. Coil1-BDPs were fluid-released post-injury, while coil2-BDPs remained intracellular. Their cellular retention was explained by non-filamentous aggregation of citrulline-modified coil2-BDP’s in pathological astrocytes. Trauma-triggered proteolysis involved calpains and caspases in specific astrocyte injury states using protease inhibitors and live-dye-reporter imaging. These novel data link TBI biofluid GFAP fragments with assembly-defective GFAP aggregation in pathological astrocytes. Clinical TBI outcome correlated with GFAP degradation rather than with overall GFAP release. These translational findings indicate that TBI biomarker GFAP undergoes degradation and modification alongside astrocyte pathology, providing a new conceptual framework for investigating biomarker-associated astrocyte proteinopathy potentially linked to post-traumatic neurodegeneration.

Supplementary Information: The online version contains supplementary material available at 10.1186/s40478-026-02240-y.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability

Dataset for longitudinal CSF quantification of GFAP and its fragments is available in Open Data Commons TBI: https://doi.org/10.34945/F5KP48. MS raw data for label-free ion quantification of GFAP fragments peptides is available at the Center for Computational Mass Spectrometry Proteomics Software MS Interactive Virtual Environment server (CCMS ProteoSAFe MassIVE): https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000099415. The preprint is available on BioRXiv: 10.1101/2025.08.01.668181.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 30 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 15 authors, 8 keywords, 13 MeSH terms, 7 funders, 108 references, 1 RRID.

Cite

This paper

Wanner, I.-B., Halford, J., Lopez, J., Shen, S., Chen, Y., Zhao, H., Salas, C., Loo, R. O., Robicsek, S., Ellingson, B. M., Gornbein, J., Van Meter, T. E., Shaw, G., Loo, J. A., & Vespa, P. M. (2026). GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome. Acta neuropathologica communications, 14(1), 101. https://doi.org/10.1186/s40478-026-02240-y

BibTeX

@article{wanner2026gfap,
author = {Wanner, Ina-Beate and Halford, Julia and Lopez, Jonathan and Shen, Sean and Chen, Yu and Zhao, Hayden and Salas, Carolina and Loo, Rachel Ogorzalek and Robicsek, Steven and Ellingson, Benjamin M and Gornbein, Jeffrey and Van Meter, Timothy E and Shaw, Gerry and Loo, Joseph A and Vespa, Paul M},
title = {{GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome}},
journal = {Acta neuropathologica communications},
year = {2026},
month = apr,
volume = {14},
number = {1},
pages = {101},
publisher = {BMC},
issn = {2051-5960},
doi = {10.1186/s40478-026-02240-y},
url = {https://doi.org/10.1186/s40478-026-02240-y},
pmid = {42032706},
pmcid = {PMC13107622}
}

RIS

TY - JOUR
AU - Wanner, Ina-Beate
AU - Halford, Julia
AU - Lopez, Jonathan
AU - Shen, Sean
AU - Chen, Yu
AU - Zhao, Hayden
AU - Salas, Carolina
AU - Loo, Rachel Ogorzalek
AU - Robicsek, Steven
AU - Ellingson, Benjamin M
AU - Gornbein, Jeffrey
AU - Van Meter, Timothy E
AU - Shaw, Gerry
AU - Loo, Joseph A
AU - Vespa, Paul M
TI - GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome
T2 - Acta neuropathologica communications
J2 - Acta Neuropathol Commun
PY - 2026
DA - 2026/04/24
VL - 14
IS - 1
SP - 101
SN - 2051-5960
PB - BMC
DO - 10.1186/s40478-026-02240-y
UR - https://doi.org/10.1186/s40478-026-02240-y
LA - en
ER -

CSL-JSON

{
"id": "10.1186/s40478-026-02240-y",
"type": "article-journal",
"title": "GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome",
"container-title": "Acta neuropathologica communications",
"author": [
{
"family": "Wanner",
"given": "Ina-Beate"
},
{
"family": "Halford",
"given": "Julia"
},
{
"family": "Lopez",
"given": "Jonathan"
},
{
"family": "Shen",
"given": "Sean"
},
{
"family": "Chen",
"given": "Yu"
},
{
"family": "Zhao",
"given": "Hayden"
},
{
"family": "Salas",
"given": "Carolina"
},
{
"family": "Loo",
"given": "Rachel Ogorzalek"
},
{
"family": "Robicsek",
"given": "Steven"
},
{
"family": "Ellingson",
"given": "Benjamin M"
},
{
"family": "Gornbein",
"given": "Jeffrey"
},
{
"family": "Van Meter",
"given": "Timothy E"
},
{
"family": "Shaw",
"given": "Gerry"
},
{
"family": "Loo",
"given": "Joseph A"
},
{
"family": "Vespa",
"given": "Paul M"
}
],
"container-title-short": "Acta Neuropathol Commun",
"volume": "14",
"issue": "1",
"page": "101",
"DOI": "10.1186/s40478-026-02240-y",
"PMID": "42032706",
"PMCID": "PMC13107622",
"ISSN": "2051-5960",
"publisher": "BMC",
"URL": "https://doi.org/10.1186/s40478-026-02240-y",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
24
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1016/j.redox.2026.104103
Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants.
Journal: Redox biology
In common: other, 4 references
[2] doi:10.1038/s41598-026-53148-5
Neurovascular and inflammatory effects of biperiden in the acute phase of moderate traumatic brain injury: evidence from a non-human primate model.
Journal: Scientific reports
In common: traumatic brain injury, other, 3 references
[3] doi:10.3390/ijms27104248
Extracellular Vesicle and Plasma miRNAs as Candidate Biomarkers of Traumatic Brain Injury in the Context of Polytrauma.
Journal: International journal of molecular sciences
In common: traumatic brain injury, 3 references
[4] doi:10.1038/s41467-026-73036-w [code]
Single-nucleus analysis reveals human-specific oligodendrocyte polarization and conserved neuronal responses after severe traumatic brain injury.
Journal: Nature communications
In common: traumatic brain injury, 2 references
[5] doi:10.1007/s10753-026-02549-9
A Dynamic and Complex Early Inflammatory Response in Blood and Cerebrospinal Fluid of Severe Traumatic Brain Injury Patients: A Dual Platform Analysis.
Journal: Inflammation
In common: traumatic brain injury, 2 references
[6] doi:10.1038/s41467-026-70304-7
NF-κB activation in astrocytes impairs wound healing after traumatic brain injury in male mice.
Journal: Nature communications
In common: traumatic brain injury, 2 references
[7] doi:10.1371/journal.pone.0345651 [code]
Non-concussive head impacts sustained during American football correlate with changes in gut microbiome diversity and composition.
Journal: PloS one
In common: traumatic brain injury, 2 references
[8] doi:10.1038/s44385-026-00090-w
Focused ultrasound-induced cavitation in a human brain microphysiological system produces injury signaling biomarkers consistent with blast trauma.
Journal: npj biomedical innovations
In common: other, 2 references
[9] doi:10.3389/fcell.2026.1876873
Multi-omics integration reveals TIM-4 as a master regulatory hub of neuroinflammation and neuronal cell death.
Journal: Frontiers in cell and developmental biology
In common: traumatic brain injury, 2 references
[10] doi:10.3390/ijms27093934 [code]
Serum Neurofilament Light Chain and GFAP Levels Are Associated with Structural Brain Connectivity in Parkinson's Disease.
Journal: International journal of molecular sciences
In common: other, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.